Details for Patent: 9,474,754

Which drugs does patent 9,474,754 protect, and when does it expire?

Patent 9,474,754 protects BRAFTOVI and is included in one NDA.

This patent has fifty-six patent family members in forty countries.

Summary for Patent: 9,474,754

Title:	Pharmaceutical combinations comprising a B-RAF inhibitor, and EGFR inhibitor and optionally a PI3K-α inhibitor
Abstract:	A pharmaceutical combination comprising (a) a B-Raf inhibitor, (b) a EGFR inhibitor and, optionally, (c) a PI3K inhibitor; the uses of such combination in the treatment of proliferative diseases; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination.
Inventor(s):	Giordano Caponigro, Darrin Stuart, Laure Moutouh-de Parseval
Assignee:	Array Biopharma Inc
Application Number:	US14/419,256
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,474,754
Patent Claim Types: see list of patent claims	Use; Formulation; Delivery;

Drugs Protected by US Patent 9,474,754

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Array Biopharma Inc	BRAFTOVI	encorafenib	CAPSULE;ORAL	210496-002	Jun 27, 2018		RX	Yes	Yes	9,474,754					BRAFTOVI, IN COMBINATION WITH CETUXIMAB AND FLUOROURACIL- BASED CHEMOTHERAPY, FOR THE TREATMENT OF ADULT PATIENTS WITH METASTATIC COLORECTAL CANCER (MCRC) WITH A BRAF V600E MUTATION, AS DETECTED BY AN FDA-AUTHORIZED TEST
Array Biopharma Inc	BRAFTOVI	encorafenib	CAPSULE;ORAL	210496-002	Jun 27, 2018		RX	Yes	Yes	9,474,754					BRAFTOVI IS A KINASE INHIBITOR INDICATED IN COMBINATION WITH CETUXIMAB, FOR THE TREATMENT OF ADULT PATIENTS WITH METASTATIC COLORECTAL CANCER (CRC) WITH A BRAF V600E MUTATION, AS DETECTED BY AN FDA-APPROVED TEST, AFTER PRIOR THERAPY
Array Biopharma Inc	BRAFTOVI	encorafenib	CAPSULE;ORAL	210496-002	Jun 27, 2018		RX	Yes	Yes	9,474,754					BRAFTOVI IS A KINASE INHIBITOR INDICATED IN COMBINATION WITH CETUXIMAB AND MFOLFOX6, FOR THE TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER (MCRC) WITH A BRAF V600E MUTATION, AS DETECTED BY AN FDA-APPROVED TEST

Foreign Priority and PCT Information for Patent: 9,474,754

PCT Information
PCT Filed	August 05, 2013	PCT Application Number:	PCT/US2013/053619
PCT Publication Date:	February 13, 2014	PCT Publication Number:	WO2014/025688

International Family Members for US Patent 9,474,754

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	092045
Australia	2013299841
Brazil	112015002384